Navigation Links
New ISHLT cardiac allograft vasculopathy standardized nomenclature
Date:6/24/2010

New York, New York, June 25, 2010 Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart progressively narrow and lead to dysfunction of the heart muscle or sudden death. Ascertaining benefit from appropriate treatment for this condition has been hampered in part because of the lack of a standard nomenclature. In an article published online today in The Journal of Heart and Lung Transplantation (www.jhltonline.org), clinicians representing the International Society for Heart and Lung Transplantation (ISHLT) Working Group on Classification of Cardiac Allograft Vasculopathy issued the first international consensus formulation of a standardized nomenclature for CAV.

"The development of cardiac allograft vasculopathy remains the Achilles heel of cardiac transplantation," commented working group leader, Mandeep R. Mehra, MD, Herbert Berger Professor and Head of Cardiology, University of Maryland School of Medicine, Baltimore, MD. "Unfortunately, the definitions of cardiac allograft vasculopathy are diverse and confusion abounds. There have been no uniform international standards for the nomenclature of this entity. The lack of a standard language has led to confusion in the interpretation of various studies and several unanswered questions persist. The ISHLT consensus statement is the first step in resolving these issues and improving cardiac transplant patient outcomes."

This consensus document, commissioned by the International Society for Heart and Lung Transplantation Board, is based on best evidence and clinical consensus derived from critical analysis of available information pertaining to angiography, intravascular ultrasound imaging, microvascular function, cardiac allograft histology, circulating immune markers, noninvasive imaging tests, and gene-based and protein-based biomarkers.

ISHLT President, John Dark, FRCS, stated, "The consensus document from the international working group led by Dr. Mehra defines the descriptors of the major clinical challenge late after cardiac transplantation. It also defines the ISHLT as the organization unifying all those, scientists and clinicians, working in this field, and able to put the stamp of authority on the recommendations. The topic is rapidly evolving, but Dr Mehra and his colleagues have undertaken to keep the data under close review. We can anticipate further definitive analyses in the future."

This article presents 5 consensus statements that describe how to best identify CAV and assess its severity. By developing a standard nomenclature, appropriate treatment options can be selected, depending on the level of CAV. Four levels of CAV are defined, ranging from CAV0 (not significant), where no angiographic lesions are detected, to CAV3 (severe), where multiple major heart vessels are involved. Key among the recommendations to define the severity of CAV is to view the anatomy of the allograft vasculature in concert with the physiological effects of the disease on cardiac allograft function.


'/>"/>

Contact: Linda Gruner
jhltmedia@elsevier.com
212-633-3923
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Cardiac MRI in the ER cuts costs, hospital admissions for chest pain patients
2. Traditional neurologic exams inadequate for predicting survival of cardiac arrest patients
3. Mediterranean Diet Linked to Better Cardiac Function
4. Surviving Cardiac Arrest Depends on Your Location
5. Chances of surviving cardiac arrest depends on your neighborhood
6. Nurse/tech symposium at TCT 2010 will address complex issues in the cardiac cath lab
7. Concerns over radiation exposure may overshadow life-saving benefits of cardiac imaging tests
8. Elsevier introduces Cardiac Electrophysiology Clinics
9. Noncardiac Chest Pain May Warrant More Management: Study
10. Coronary CTA a cost-effective alternative to cardiac catheterization for the evaluation of CAD
11. Outcomes of patients dismissed from the hospital with non-cardiac chest pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... rates are on the rise, say researchers presenting their work at the ... Canada. , “The combination of evaluating the patterns of change in concussion symptom ...
(Date:7/20/2017)... 20, 2017 (PRWEB) , ... ... ... a global provider of enterprise-grade IT operations analytics and application performance monitoring ... one of world’s largest healthcare services providers. , According to Peter Ohrenberger, ...
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of ... up with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week ... Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... FDAnews Webinar**, Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... inspections and boosting quality. , It’s known as the “CY2016 Annual FDA Medical ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... SARASOTA, Fla. , July 11, 2017  Dr. Echenberg, founder of ... Dilator therapy program to patients who suffer from painful intercourse and other ... vaginismus and vaginal atrophy due to menopause. ... VuVatech LLC ... Dilators , created by Sarasota, Florida -based start-up company, ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
Breaking Medicine Technology: